TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29249202

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 156811

Group type: EXPERIMENTAL
Intervention: Model projections with 30% treatment coverage (TC) rate
Number of subjects: 156811

Group type: EXPERIMENTAL
Intervention: Model projections with increased TC rate in HR MSM to 50%
Number of subjects: 156811

Group type: EXPERIMENTAL
Intervention: Model projections with increased TC rate in HR MSM to 70%
Number of subjects: 156811

Group type: EXPERIMENTAL
Intervention: Model projections with 30% TC rate
Number of subjects: 156811
Study: 29250012

Group type: EXPERIMENTAL
Intervention: Body-Affective Mindfulness Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29250743

Group type: EXPERIMENTAL
Intervention: Early tapering of immunosuppressive agents
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine tapering of immunosuppressive agents
Number of subjects: 63
Study: 29251207

Group type: EXPERIMENTAL
Intervention: Fast-track EVAR protocol
Number of subjects: 250
Study: 29251556

Group type: EXPERIMENTAL
Intervention: Ambrisentan and tadalafil combination therapy
Number of subjects: 21
Study: 29251709

Group type: EXPERIMENTAL
Intervention: Chronic Critical Illness (CCI) patients
Number of subjects: 145

Group type: COMPARATOR
Intervention: RAP patients
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Independent risk factors for CCI
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: CCI patients
Number of subjects: 145
Study: 29251799

Group type: EXPERIMENTAL
Intervention: Atrioventricular junction ablation (AVJA)
Number of subjects: 3358

Group type: COMPARATOR
Intervention: Rate-slowing drugs
Number of subjects: 3358

Group type: COMPARATOR
Intervention: Sinus rhythm (SR) patients
Number of subjects: 3358
Study: 29251951

Group type: EXPERIMENTAL
Intervention: Socially Disconnected subgroup
Number of subjects: 1571

Group type: COMPARATOR
Intervention: High Stress/High Contact subgroup
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Risky Friends and Low Contact subgroup
Number of subjects: 1571
Study: 29252124

Group type: EXPERIMENTAL
Intervention: M6620 (ATR inhibitor) + Topotecan (1.25 mg/m²)
Number of subjects: 21
Study: 29253081

Group type: EXPERIMENTAL
Intervention: Cohort A: Four cycles of dose-dense doxorubicin and cyclophosphamide, followed by 12 doses of standard paclitaxel plus four cycles of trastuzumab and pertuzumab.
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cohort B: Four cycles of standard fluorouracil/epirubicin/cyclophosphamide, followed by four cycles of docetaxel with four cycles of trastuzumab and pertuzumab.
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cohort A: Pertuzumab, trastuzumab, and chemotherapy.
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cohort B: Pertuzumab, trastuzumab, and chemotherapy.
Number of subjects: 397
Study: 29253090

Group type: EXPERIMENTAL
Intervention: HIV-uninfected women in 2011
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: HIV-uninfected women in 2012
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: Maternal RSV infection
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: Postpartum RSV infection in mothers
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: Infants with RSV illness
Number of subjects: 2310
Study: 29253097

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus Lamivudine (300 mg)
Number of subjects: 120
Study: 29253846

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study: 29253918

Group type: EXPERIMENTAL
Intervention: Motorized spiral colonoscopy (MSC)
Number of subjects: 30
Study: 29254220

Group type: EXPERIMENTAL
Intervention: Evaluation of PD-1, PD-L1, and PD-L2 expression in peripheral T-cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma cytokine levels
Number of subjects: 0
Study: 29254376

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 862
Study: 29254506

Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 therapy (IL-2)
Number of subjects: 1535

Group type: COMPARATOR
Intervention: No irAE
Number of subjects: 1535
Study: 29254856

Group type: EXPERIMENTAL
Intervention: Single fraction of multi-catheter interstitial high-dose rate brachytherapy (16 Gy)
Number of subjects: 26
Study: 29255413

Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paleolithic diet with combined aerobic and resistance exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (lifestyle ± metformin without intervention)
Number of subjects: 0
Study: 29256049

Group type: EXPERIMENTAL
Intervention: OUFCC (urinary free cortisol corrected for creatinine)
Number of subjects: 26
Study: 29256908

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS applied to the right inferior frontal gyrus for 10 days (Monday through Friday for 2 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 9
Study: 29257710

Group type: EXPERIMENTAL
Intervention: PT2385 at 800 mg twice per day (RP2D)
Number of subjects: 51
Study: 29258438

Group type: EXPERIMENTAL
Intervention: Supreme™ laryngeal mask airway (SLMA)
Number of subjects: 584
Study: 29258468

Group type: EXPERIMENTAL
Intervention: BD depression
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: UP
Number of subjects: 88

Group type: COMPARATOR
Intervention: mania and mixed states
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mean activity over 24 hours
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Non-linear variability measures of activity
Number of subjects: 88
Study: 29258560

Group type: EXPERIMENTAL
Intervention: Intensive therapy (4 hours each weekday for 10 treatment days)
Number of subjects: 3
Study: 29258585

Group type: EXPERIMENTAL
Intervention: Endurance training for 26 weeks
Number of subjects: 13
Study: 29258618

Group type: EXPERIMENTAL
Intervention: Autologous tumor-derived autophagosome vaccine (DRibbles)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m²
Number of subjects: 4
Study: 29258674

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus ipilimumab followed by surgery
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard preoperative chemotherapy (platinum doublet regimen) followed by surgery
Number of subjects: 55
Study: 29258913

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 14873
Study: 29258976

Group type: EXPERIMENTAL
Intervention: Personalized HIV testing recommendation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard HIV testing information
Number of subjects: 236
Study: 29258978

Group type: EXPERIMENTAL
Intervention: SMS messages and community BP measurement through task shifting with electronic transfer of measures to the patient and health care team members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 0
Study: 29259073

Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg IV every 14 days)
Number of subjects: 9
Study: 29259809

Group type: EXPERIMENTAL
Intervention: Tension night splint (TNS) + home exercise programme (HEP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home exercise programme (HEP) only
Number of subjects: 40
Study: 29259822

Group type: EXPERIMENTAL
Intervention: PTM202 (bovine colostrum and hyperimmune hen's egg)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PTM202
Number of subjects: 301
Study: 29259998

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation of the left prefrontal cortex (PFC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation of the primary motor cortex (MC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 33
Study: 29260460

Group type: EXPERIMENTAL
Intervention: Second-line antidiabetic treatment
Number of subjects: 2000
Study: 29260603

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach, 12 sessions, twice a week, with an additional session for parents' orientation.
Number of subjects: 8
Study: 29261402

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Number of subjects: 30
Study: 29261567

Group type: EXPERIMENTAL
Intervention: Partial pressure of arterial carbon dioxide (pCO2)
Number of subjects: 600
Study: 29263019

Group type: EXPERIMENTAL
Intervention: Ranolazine (500-1000 mg twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subgroup with improved angina (SAQ-7)
Number of subjects: 30
Study: 29263032

Group type: EXPERIMENTAL
Intervention: Plant protein substitution for animal protein
Number of subjects: 0
Study: 29263061

Group type: EXPERIMENTAL
Intervention: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) in subjects with chronic kidney disease
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under dialysis conditions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under nondialysis conditions
Number of subjects: 46
Study: 29263070

Group type: EXPERIMENTAL
Intervention: Alalevonadifloxacin (1,000 mg twice daily for 5 days)
Number of subjects: 30
Study: 29263704

Group type: EXPERIMENTAL
Intervention: HIPEC with fast-track recovery strategy
Number of subjects: 9
Study: 29263894

Group type: EXPERIMENTAL
Intervention: CART-20 cells (autologous anti-CD20 CAR-modified T cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29264713

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 417

Group type: COMPARATOR
Intervention: Liraglutide 0.9 mg
Number of subjects: 417
Study: 29264930

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No extended treatment
Number of subjects: 0
Study: 29265773

Group type: EXPERIMENTAL
Intervention: LAP-BAND (Apollo Endosurgery Inc.) adjustable gastric banding system
Number of subjects: 652
Study: 29265961

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment using modified standardized assessments, functional assessments, and caregiver/informant reports.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive behavior measures, out-of-range developmental assessments, and social-communication measures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended framework for neuropsychological evaluation.
Number of subjects: 0
Study: 29266363

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 12
Study: 29266856

Group type: EXPERIMENTAL
Intervention: Chikungunya arthritis patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chikungunya virus infection
Number of subjects: 38
Study: 29267317

Group type: EXPERIMENTAL
Intervention: CholangioFlex (0.6mm probe)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AlveoFlex (1.4mm probe)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both probes
Number of subjects: 48
Study: 29267575

Group type: EXPERIMENTAL
Intervention: XEN45 gel stent implantation
Number of subjects: 15
Study: 29267856

Group type: EXPERIMENTAL
Intervention: Pazopanib (PZ)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Quality-adjusted progression-free survival (QAPFS) with PZ
Number of subjects: 940

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 940
Study: 29267946

Group type: EXPERIMENTAL
Intervention: Lower cardiovagal tone and baroreflex sensitivity in type 2 diabetes patients
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (glucose-tolerant individuals)
Number of subjects: 206
Study: 29267966

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Copeptin and AVP
Number of subjects: 91
Study: 29268712

Group type: EXPERIMENTAL
Intervention: Long time hypertensive group
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Short time hypertensive group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 134
Study: 29268720

Group type: EXPERIMENTAL
Intervention: Falls efficacy measured by the Modified Falls Efficacy Scale (MFES)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Low baseline falls efficacy
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: High falls efficacy but poor postural balance
Number of subjects: 247
Study: 29268722

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) every 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-contrast liver MRI every 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic liver CT for confirmation of HCC diagnosis if a focal liver lesion is detected
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival of patients who developed HCC within the 3-year follow-up period
Number of subjects: 0
Study: 29268739

Group type: EXPERIMENTAL
Intervention: Nasal gene expression profiling
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bronchial gene expression analysis
Number of subjects: 53
Study: 29268751

Group type: EXPERIMENTAL
Intervention: Long-term exposure to ambient particulate matter <2.5 μm (PM2.5)
Number of subjects: 6253

Group type: COMPARATOR
Intervention: Baseline prevalence of AVC
Number of subjects: 6253

Group type: COMPARATOR
Intervention: Baseline prevalence of MAC
Number of subjects: 6253

Group type: COMPARATOR
Intervention: Baseline prevalence of CAC
Number of subjects: 6253
Study: 29268758

Group type: EXPERIMENTAL
Intervention: Pamphlet provided by reception staff addressing barriers and enablers to registration, along with an Internet-enabled tablet for registration.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control period (no intervention) for 2 weeks before the intervention starts.
Number of subjects: 6
Study: 29268807

Group type: EXPERIMENTAL
Intervention: 24-h dietary recalls (EIrecall) in SBS group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Doubly labelled water method (TEEdlw) in SBS group
Number of subjects: 22

Group type: COMPARATOR
Intervention: 24-h dietary recalls (EIrecall) in control group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Doubly labelled water method (TEEdlw) in control group
Number of subjects: 22
Study: 29268922

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 197

Group type: COMPARATOR
Intervention: dPR (diastolic pressure ratio)
Number of subjects: 197

Group type: COMPARATOR
Intervention: dPR (diastolic pressure ratio) during 25% to 75% of diastole
Number of subjects: 197
Study: 29268924

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1334
Study: 29268926

Group type: EXPERIMENTAL
Intervention: Transfemoral THV implantation
Number of subjects: 203
Study: 29269252

Group type: EXPERIMENTAL
Intervention: Nestorone®/ethinyl estradiol contraceptive vaginal ring (CVR)
Number of subjects: 905
Study: 29269441

Group type: EXPERIMENTAL
Intervention: Microbial dysbiosis presence during exacerbations
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Microbiome composition analysis
Number of subjects: 281
Study: 29269559

Group type: EXPERIMENTAL
Intervention: Point-of-care CRP alongside vital signs and objective symptoms measurements
Number of subjects: 5517

Group type: EXPERIMENTAL
Intervention: Point-of-care CRP
Number of subjects: 5517
Study: 29269579

Group type: EXPERIMENTAL
Intervention: Video-assisted mediastinoscopy (VAM) or VAM-lymphadenectomy (VAMLA)
Number of subjects: 105
Study: 29269583

Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29269796

Group type: EXPERIMENTAL
Intervention: Intravenous pentamidine at 4 mg/kg (maximum 300 mg)
Number of subjects: 50
Study: 29269980

Group type: EXPERIMENTAL
Intervention: Salivary GPX
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary TAC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary MDA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary SOD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary UA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary 8-OHdG
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Salivary SOD, TAC, GPX, UA
Number of subjects: 75
Study: 29270013

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29270062

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (sabr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors affecting accrual (including institutional, clinician, and patient factors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication and education efforts directed at referring physicians
Number of subjects: 0
Study: 29270080

Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 31
Study: 29270208

Group type: EXPERIMENTAL
Intervention: Proactive telephone support (daily calls initiated by a breastfeeding support team)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Reactive telephone support (mothers could call the breastfeeding support team)
Number of subjects: 365
Study: 29270312

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard services (control)
Number of subjects: 80
Study: 29270487

Group type: EXPERIMENTAL
Intervention: Fresolimumab 1 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fresolimumab 4 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29270685

Group type: EXPERIMENTAL
Intervention: BoNT-A treatment
Number of subjects: 1036
Study: 29270725

Group type: EXPERIMENTAL
Intervention: Uterus transplantation from a 46-year-old mother to a 23-year-old daughter; surgery duration: 12.12/5.95 hours.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Uterus transplantation attempt from a 61-year-old donor; surgery duration: 13.10 hours.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Uterus transplantation from a 46-year-old mother to a 23-year-old daughter; surgery duration: 9.05/4.52 hours.
Number of subjects: 3
Study: 29270781

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg maximum dose)
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1723
Study: 29270787

Group type: EXPERIMENTAL
Intervention: FDG PET/CT at baseline (PET0), after induction (PET-AI), and end of treatment (PET-EoT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: FDG PET/CT scans analyzed using Krippendorff's alpha coefficient
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) for positivity thresholds (DS 2, 3, 4, 5)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: IMPeTUs criteria for PET interpretation
Number of subjects: 86
Study: 29270788

Group type: EXPERIMENTAL
Intervention: F18-choline PET/CT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: F18-choline PET/CT guided surgery
Number of subjects: 25
Study: 29270800

Group type: EXPERIMENTAL
Intervention: Intraperitoneal PVDF mesh enhanced with iron particles (DynaMesh IPOM visible)
Number of subjects: 15
Study: 29271373

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1792

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1792

Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 1792
Study: 29271830

Group type: EXPERIMENTAL
Intervention: Point-of-care creatinine assay
Number of subjects: 0
Study: 29272162

Group type: EXPERIMENTAL
Intervention: CTC0 (circulating tumor cell nonzero at baseline and 0 at 13 weeks)
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: CTC conversion (≥ 5 CTCs at baseline, ≤ 4 at 13 weeks)
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: 30% decrease in CTC count
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: 50% decrease in CTC count
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: 70% decrease in CTC count
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: 30% decrease in PSA level
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: 50% decrease in PSA level
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: 70% decrease in PSA level
Number of subjects: 6081
Study: 29272364

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) dose-escalation cohort, 1.8 mg/kg IV every 3 weeks for two cycles, escalated to 2.4 mg/kg for patients with stable disease or partial response.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) standard/fixed-dose cohort.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) as a bridge to autologous hematopoietic cell transplantation (AHCT).
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients in CR at the time of AHCT.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients who proceeded to AHCT directly after receiving BV alone.
Number of subjects: 56
Study: 29272368

Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 400
Study: 29272443

Group type: EXPERIMENTAL
Intervention: Monthly DHA-PQ (2880 mg PQ)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Weekly DHA-PQ (960 mg PQ)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Low-dose daily DHA-PQ (320 or 160 mg PQ)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Low daily DHA-PQ dosing
Number of subjects: 83
Study: 29272480

Group type: EXPERIMENTAL
Intervention: Endomicroscopic mucosal healing score (eMHs) after 3 anti-TNF applications
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 23
Study: 29272906

Group type: EXPERIMENTAL
Intervention: Stylet slow-pull technique
Number of subjects: 121

Group type: COMPARATOR
Intervention: Suction technique
Number of subjects: 121